Latency Reversing Agents and the Road to an HIV Cure
Pathogens · 2025-02-27 · 14 (3) · 232
DOI: 10.3390/pathogens14030232 ↗At a glance
Übersichtsarbeit in Pathogens, published online on 2025-02-27. Written by Louis Tioka and 3 co-authors. Institution: Faculty of Medicine, Erlangen-Nürnberg, Friedrich-Alexander-Universität, 91054 Erlangen, Germany. Major MEDLINE topics: Virus Latency, HIV Infections, HIV-1, Anti-HIV Agents. Cited 25 times so far (Crossref); 136 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
HIV-1 infection cannot be cured due to the presence of HIV-1 latently infected cells. These cells do not produce the virus, but they can resume virus production at any time in the absence of antiretroviral therapy. Therefore, people living with HIV (PLWH) need to take lifelong therapy. Strategies have been coined to eradicate the viral reservoir by reactivating HIV-1 latently infected cells and subsequently killing them. Various latency reversing agents (LRAs) that can reactivate HIV-1 in vitro and ex vivo have been identified. The most potent LRAs also strongly activate T cells and therefore cannot be applied in vivo. Many LRAs that reactivate HIV in the absence of general T cell activation have been identified and have been tested in clinical trials. Although some LRAs could reduce the reservoir size in clinical trials, so far, they have failed to eradicate the reservoir. More recently, immune modulators have been applied in PLWH, and the first results seem to indicate that these may reduce the reservoir and possibly improve immunological control after therapy interruption. Potentially, combinations of LRAs and immune modulators could reduce the reservoir size, and in the future, immunological control may enable PLWH to live without developing HIV-related disease in the absence of therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Erlangen-Nürnberg, Friedrich-Alexander-Universität, 91054 Erlangen, Germany.
- Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, 17177 Stockholm, Sweden.
- Department of Infectious Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.
- Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.
ORCID profiles: Anders Sönnerborg, Maarten A A van de Klundert
Cite
APA
Tioka, L., Diez, R. C., Sönnerborg, A., & van de Klundert, M. A. A. (2025). Latency Reversing Agents and the Road to an HIV Cure. Pathogens, 14(3), 232. https://doi.org/10.3390/pathogens14030232
Vancouver
Tioka L, Diez RC, Sönnerborg A, van de Klundert MAA. Latency Reversing Agents and the Road to an HIV Cure. Pathogens. 2025;14(3):232. doi:10.3390/pathogens14030232
BibTeX
@article{Tioka2025,
author = {Tioka, Louis and Diez, Rafael Ceña and Sönnerborg, Anders and van de Klundert, Maarten A A},
title = {Latency Reversing Agents and the Road to an HIV Cure},
journal = {Pathogens},
year = {2025},
volume = {14},
number = {3},
pages = {232},
doi = {10.3390/pathogens14030232}
}
EUVIMED